Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05602649 · ClinicalTrials.gov registry record · Phase 1
The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles
A Phase 1 study of Cannabis Use, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05602649: Recruiting Phase 1 study of Cannabis Use, sponsored by Johns Hopkins University.
NCT05602649 is a Phase 1 study of Cannabis Use that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 80 participants, below the 278-participant average among 44 other Cannabis Use trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05602649, a Phase 1 study of Cannabis Use, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the pharmacokinetics and pharmacodynamics of delta-9-tetrahydrocannabinol (THC)-infused chocolates, gummies, and drinks. Healthy adults (N=40) will complete 9 drug administration sessions, including an overnight stay prior to each session. Participants will consume THC containing products in a fasted state; following drug administration, the participants will complete cognitive and psychomotor tasks, subjective assessments, have blood collected, and vital signs monitored.
Primary Outcome
Computerized version of Paced Auditory Serial Addition Task will be administered to assess working memory performance. Total correct trials out of 90 recorded is primary outcome (lower scores indicate worse performance).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabis
Study Locations (1)
Maryland
- Johns Hopkins Behavioral Pharmacology Research Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-07-10 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT05602649 shows while recruiting
NCT05602649 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 278-participant average among 44 other Cannabis Use trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Cannabis Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05602649 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05602649 about?
NCT05602649 is a clinical study titled "The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles". This study will examine the pharmacokinetics and pharmacodynamics of delta-9-tetrahydrocannabinol (THC)-infused chocolates, gummies, and drinks. Healthy adults (N=40) will complete 9 drug administration sessions, including an overnight stay prior to each session. Participants will consume THC contai...
What is the current status of trial NCT05602649?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-07-10. Estimated completion is 2027-01.
What conditions does trial NCT05602649 study?
This clinical trial studies the following conditions: Cannabis Use.
What interventions are being tested in trial NCT05602649?
The interventions under investigation include: Placebo (DRUG), Cannabis (DRUG).
Who is sponsoring clinical trial NCT05602649?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05602649 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05602649's enrollment target sits among peer trials
80 27th of 44 higher than 17 of 44 other Cannabis Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Cannabis on Cigarette Use Behavior
RECRUITING · Phase 1
-
SV2A in Older Adults
RECRUITING · Phase 1
-
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
RECRUITING · Phase 1
-
Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development
RECRUITING · Phase 1
-
Effect of Cannabis on E-Cigarette Use Behavior
RECRUITING · Phase 1
-
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI